VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 158 filers reported holding VERVE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $454 | -57.1% | 92,975 | +16.7% | 0.00% | – |
| Q1 2024 | $1,058 | -61.0% | 79,657 | -59.1% | 0.00% | -100.0% |
| Q4 2023 | $2,712 | +41.8% | 194,628 | +35.0% | 0.00% | 0.0% |
| Q3 2023 | $1,912 | -16.0% | 144,218 | +18.9% | 0.00% | 0.0% |
| Q2 2023 | $2,275 | +45.0% | 121,320 | +11.5% | 0.00% | 0.0% |
| Q1 2023 | $1,569 | -59.9% | 108,846 | -46.2% | 0.00% | -50.0% |
| Q4 2022 | $3,917 | -99.9% | 202,389 | +78.0% | 0.00% | -50.0% |
| Q3 2022 | $3,905,000 | +5177.0% | 113,671 | +2240.8% | 0.00% | – |
| Q2 2022 | $74,000 | -87.0% | 4,856 | -80.6% | 0.00% | – |
| Q1 2022 | $571,000 | – | 24,995 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $37,665,169 | 23.26% |
| Alphabet Inc. | 10,549,086 | $197,795,362 | 10.63% |
| Casdin Capital, LLC | 2,360,571 | $44,260,706 | 3.87% |
| MPM BioImpact LLC | 857,940 | $16,086,375 | 3.24% |
| Redmile Group, LLC | 1,061,960 | $19,911,750 | 0.76% |
| Novo Holdings A/S | 500,000 | $9,375,000 | 0.72% |
| ARK Investment Management | 5,150,851 | $96,578,455 | 0.64% |
| Avidity Partners Management LP | 878,600 | $16,473,750 | 0.58% |
| Nikko Asset Management Americas, Inc. | 2,185,857 | $40,941,102 | 0.43% |
| Cormorant Asset Management, LP | 350,000 | $6,562,500 | 0.37% |